{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,12,2]],"date-time":"2025-12-02T06:30:24Z","timestamp":1764657024110,"version":"3.46.0"},"reference-count":71,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2025,12,2]],"date-time":"2025-12-02T00:00:00Z","timestamp":1764633600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Immunol."],"abstract":"<jats:p>Cervical cancer is the fourth most prevalent oncological condition affecting the global female population in 2022, considering both disease occurrence and fatality rates. Although surgical intervention is the curative approach for early stage cervical cancer, recurrent progression is associated with unfavorable clinical outcomes. The current therapeutic protocols outlined in the National Comprehensive Cancer Network Guidelines 4.2025 edition propose that for second-line or subsequent therapies of cervical carcinoma, prioritized protocols incorporate pembrolizumab administration specifically for patients demonstrating high tumor mutational burden characteristics, positive for programmed cell death ligand 1 expression, or exhibiting microsatellite instability-high\/mismatch repair deficiency molecular profiles. Other proposed therapeutic approaches include bevacizumab, paclitaxel, and nanoparticle albumin-bound paclitaxel (nab-paclitaxel). To date, no standardized systemic combination protocol has been established for the management of recurrent\/metastatic cervical carcinoma after first-line treatment. The clinical application of camrelizumab combined with nab-paclitaxel as a second-line intervention for recurrent human papillomavirus (HPV)-associated cervical cancer remains rare in existing medical literature. This case report documents complete remission achieved through second-line camrelizumab combined with nab-paclitaxel therapy in a 65-year-old Chinese female with recurrent HPV-associated cervical cancer with positive programmed cell death ligand 1 (PD-L1) in whom initial treatment failed. Clinical outcomes included the disease-free survival of 22 months, accompanied by the first progression-free survival (PFS1) of 10 months and the PFS2 of 58 months. The overall survival was recorded at 92 months. The patient continues to undergo active clinical surveillance. Our case report illustrates that second-line immunochemotherapy utilizing camrelizumab in combination with nab-paclitaxel exhibits notable efficacy and manageable safety profile.<\/jats:p>","DOI":"10.3389\/fimmu.2025.1679950","type":"journal-article","created":{"date-parts":[[2025,12,2]],"date-time":"2025-12-02T06:26:45Z","timestamp":1764656805000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":0,"title":["Complete remission of recurrent human papillomavirus-associated cervical cancer managed with camrelizumab and nanoparticle albumin-bound paclitaxel as second-line treatment: a case report"],"prefix":"10.3389","volume":"16","author":[{"given":"Liping","family":"Sun","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Juan","family":"Lang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xueya","family":"Wu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Dan","family":"Shi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jiefeng","family":"Sang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zhongkui","family":"Xiong","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1965","published-online":{"date-parts":[[2025,12,2]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.3322\/caac.21834","article-title":"Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries","volume":"74","author":"Bray","year":"2024","journal-title":"CA: Cancer J Clin"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.1002\/ijc.35369","article-title":"Global landscape of cervical cancer incidence and mortality in 2022 and predictions to 2030: The urgent need to address inequalities in cervical cancer","volume":"157","author":"Li","year":"2025","journal-title":"Int J Cancer"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2022.849352","article-title":"PD-1\/PD-L1 inhibitors for advanced or metastatic cervical cancer: From bench to bed","volume":"12","author":"Huang","year":"2022","journal-title":"Front Oncol"},{"key":"B4","doi-asserted-by":"publisher","first-page":"1002296","DOI":"10.37349\/etat.2025.1002296","article-title":"Immunotherapy in cervical cancer: an innovative approach for better treatment outcomes","volume":"6","author":"Dey","year":"2025","journal-title":"Explor targeted anti-tumor Ther"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2024.1450875","article-title":"Oncoproteins E6 and E7 upregulate topoisomerase I to activate the cGAS-PD-L1 pathway in cervical cancer development","volume":"15","author":"Luo","year":"2024","journal-title":"Front Pharmacol"},{"key":"B6","doi-asserted-by":"publisher","first-page":"109449","DOI":"10.1016\/j.abb.2022.109449","article-title":"Human papillomavirus 16 E6\/E7 contributes to immune escape and progression of cervical cancer by regulating miR-142-5p\/PD-L1 axis","volume":"731","author":"Ling","year":"2022","journal-title":"Arch Biochem biophysics"},{"key":"B7","doi-asserted-by":"publisher","first-page":"1260","DOI":"10.3390\/cancers17081260","article-title":"Advances and challenges in the treatment of HPV-associated lower genital tract cancers by immune checkpoint blockers: insights from basic and clinical science","volume":"17","author":"Zafar","year":"2025","journal-title":"Cancers"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.1089\/cbr.2025.0031","article-title":"Immunotherapeutics in clinical trials for cervical cancer","volume":"40","author":"Yadagiri","year":"2025","journal-title":"Cancer biotherapy radiopharmaceuticals"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.1002\/advs.202412574","article-title":"Radiotherapy-associated cellular senescence and EMT alterations contribute to distinct disease relapse patterns in locally advanced cervical cancer","volume":"12","author":"Zhang","year":"2025","journal-title":"Advanced science"},{"key":"B10","doi-asserted-by":"publisher","first-page":"e10","DOI":"10.3802\/jgo.2025.36.e10","article-title":"Efficacy and safety of cisplatin combined with paclitaxel concurrent radiotherapy in patients with locally advanced cervical squamous cell carcinoma","volume":"36","author":"Feng","year":"2025","journal-title":"J gynecologic Oncol"},{"key":"B11","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1159\/000091182","article-title":"A phase II trial with cisplatin-paclitaxel cytotoxic treatment and concurrent external and endocavitary radiation therapy in locally advanced or recurrent cervical cancer","volume":"70","author":"Miglietta","year":"2006","journal-title":"Oncology"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijrobp.2025.04.037","article-title":"Distant metastasis after chemoradiation and IGABT in locally advanced cervical cancer","volume":"123","author":"Knoth","year":"2025","journal-title":"Int J Radiat oncology biology Phys"},{"key":"B13","doi-asserted-by":"publisher","first-page":"23","DOI":"10.3390\/cancers17010023","article-title":"Impact of the number of positive pelvic lymph nodes on risk of para-aortic recurrence in patients with clinically early cervical cancer treated by a radical hysterectomy and pelvic lymphadenectomy","volume":"17","author":"Schoonhoven","year":"2024","journal-title":"Cancers"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2112435","article-title":"Pembrolizumab for persistent, recurrent, or metastatic cervical cancer","volume":"385","author":"Colombo","year":"2021","journal-title":"New Engl J Med"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.1016\/j.ygyno.2021.03.002","article-title":"Patient characteristics, treatment patterns, and clinical outcomes among patients with previously treated recurrent or metastatic cervical cancer: A community oncology-based analysis","volume":"161","author":"Alholm","year":"2021","journal-title":"Gynecologic Oncol"},{"key":"B16","doi-asserted-by":"publisher","first-page":"101930","DOI":"10.1016\/j.xcrm.2025.101930","article-title":"Neoadjuvant immunotherapy with or without chemotherapy in locally advanced oral squamous cell carcinoma: Randomized, two-arm, phase 2 trial","volume":"6","author":"Liu","year":"2025","journal-title":"Cell Rep Med"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.2147\/OTT.S400376","article-title":"Clinical efficacy and safety of immunotherapy retreatment in metastatic cervical cancer: A retrospective study","volume":"16","author":"Li","year":"2023","journal-title":"OncoTargets Ther"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.1200\/JCO-24-02495","article-title":"Camrelizumab plus famitinib versus camrelizumab alone and investigator\u2019s choice of chemotherapy in recurrent or metastatic cervical cancer: A randomized, phase II study","volume":"43","author":"Xia","year":"2025","journal-title":"J Clin Oncol"},{"key":"B19","doi-asserted-by":"publisher","first-page":"110121","DOI":"10.1016\/j.ejso.2025.110121","article-title":"Predictors of recurrence in early-stage cervical cancer without adjuvant treatment after radical surgery","volume":"51","author":"Caruso","year":"2025","journal-title":"Eur J Surg Oncol"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.7150\/jca.50752","article-title":"The clinical and prognostic implication of deep stromal invasion in cervical cancer patients undergoing radical hysterectomy","volume":"11","author":"Zhu","year":"2020","journal-title":"J Cancer"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(23)00147-X","article-title":"Adjuvant chemotherapy following chemoradiotherapy as primary treatment for locally advanced cervical cancer versus chemoradiotherapy alone (OUTBACK): an international, open-label, randomised, phase 3 trial","volume":"24","author":"Mileshkin","year":"2023","journal-title":"Lancet Oncol"},{"key":"B22","doi-asserted-by":"publisher","first-page":"308","DOI":"10.3892\/ol.2025.15054","article-title":"Intermediate\u2212risk factors affecting oncological outcome in patients with FIGO 2018 stage IB2 cervical cancer who do not receive adjuvant therapy","volume":"29","author":"Tokalioglu","year":"2025","journal-title":"Oncol letters"},{"key":"B23","doi-asserted-by":"publisher","first-page":"364","DOI":"10.1186\/s12885-024-13282-7","article-title":"Predictors of distant metastasis or local recurrent after radiotherapy in patients with cervical cancer","volume":"25","author":"Wu","year":"2025","journal-title":"BMC cancer"},{"key":"B24","doi-asserted-by":"publisher","first-page":"e2","DOI":"10.3802\/jgo.2025.36.e2","article-title":"Comparison of postoperative adjuvant platinum-based chemotherapy and no further therapy after radical surgery in intermediate-risk early-stage cervical cancer","volume":"36","author":"Nishimura","year":"2025","journal-title":"J gynecologic Oncol"},{"key":"B25","doi-asserted-by":"publisher","DOI":"10.1136\/ijgc-2020-001974","article-title":"Role of adjuvant therapy after radical hysterectomy in intermediate-risk, early-stage cervical cancer","volume":"31","author":"Cao","year":"2021","journal-title":"Int J gynecological Cancer"},{"key":"B26","doi-asserted-by":"publisher","first-page":"1320","DOI":"10.3390\/cancers17081320","article-title":"Adjuvant therapy in \u201cIntermediate-risk\u201d Early-stage cervical cancer: to treat or not to treat? Systematic review and meta-analysis","volume":"17","author":"Ripepi","year":"2025","journal-title":"Cancers"},{"key":"B27","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijrobp.2017.03.029","article-title":"Prognostic importance of the site of recurrence in patients with metastatic recurrent cervical cancer","volume":"98","author":"Kim","year":"2017","journal-title":"Int J Radiat oncology biology physics"},{"key":"B28","doi-asserted-by":"publisher","first-page":"e99","DOI":"10.3802\/jgo.2025.36.e99","article-title":"Oncologic outcome of metachronous oligometastatic recurrence in advanced cervical cancer patients after primary radio-chemotherapy","volume":"36","author":"Bartl","year":"2025","journal-title":"J gynecologic Oncol"},{"key":"B29","doi-asserted-by":"publisher","DOI":"10.1006\/gyno.1997.4855","article-title":"Radiotherapy for centrally recurrent cervical cancer of the vaginal stump following hysterectomy","volume":"67","author":"Ito","year":"1997","journal-title":"Gynecologic Oncol"},{"key":"B30","doi-asserted-by":"publisher","DOI":"10.18999\/nagjms.81.3.351","article-title":"High-dose-rate intracavitary brachytherapy for recurrent cervical cancer in the vaginal stump after hysterectomy","volume":"81","author":"Kozai","year":"2019","journal-title":"Nagoya J Med science"},{"key":"B31","doi-asserted-by":"publisher","first-page":"1240","DOI":"10.3390\/cancers17071240","article-title":"Intraoperative radiation therapy for gynecologic Malignancies: when is it indicated","volume":"17","author":"Pagano","year":"2025","journal-title":"Cancers"},{"key":"B32","doi-asserted-by":"publisher","first-page":"905","DOI":"10.1186\/s12885-023-11406-z","article-title":"Salvage radiotherapy strategy and its prognostic significance for patients with locoregional recurrent cervical cancer after radical hysterectomy: a multicenter retrospective 10-year analysis","volume":"23","author":"Shan","year":"2023","journal-title":"BMC cancer"},{"key":"B33","doi-asserted-by":"publisher","first-page":"871","DOI":"10.1186\/s12885-024-12617-8","article-title":"Salvage radiotherapy for locally recurrent cervical and endometrial carcinoma: clinical outcomes and toxicities","volume":"24","author":"Cong","year":"2024","journal-title":"BMC cancer"},{"key":"B34","doi-asserted-by":"publisher","first-page":"101802","DOI":"10.1016\/j.ijgc.2025.101802","article-title":"Patterns of pembrolizumab use for recurrent cervical cancer","volume":"35","author":"Huang","year":"2025","journal-title":"Int J gynecological Cancer"},{"key":"B35","doi-asserted-by":"publisher","first-page":"47","DOI":"10.1007\/s12032-022-01646-7","article-title":"Balstilimab and other immunotherapy for recurrent and metastatic cervical cancer","volume":"39","author":"Bose","year":"2022","journal-title":"Med Oncol"},{"key":"B36","doi-asserted-by":"publisher","first-page":"1122","DOI":"10.3332\/ecancer.2020.1122","article-title":"Recurrent cervical cancer treated with palliative chemotherapy: real-world outcome","volume":"14","author":"Mailankody","year":"2020","journal-title":"Ecancermedicalscience"},{"key":"B37","doi-asserted-by":"publisher","DOI":"10.1016\/S0002-9378(16)33384-1","article-title":"Immunotherapy and chemotherapy of gynecologic cancers","volume":"124","author":"Pattillo","year":"1976","journal-title":"Am J obstetrics gynecology"},{"key":"B38","doi-asserted-by":"publisher","first-page":"65","DOI":"10.1016\/j.annonc.2024.10.002","article-title":"Pembrolizumab plus chemotherapy for advanced and recurrent cervical cancer: final analysis according to bevacizumab use in the randomized KEYNOTE-826 study","volume":"36","author":"Lorusso","year":"2025","journal-title":"Ann Oncol Off J Eur Soc Med Oncology\/ESMO"},{"key":"B39","doi-asserted-by":"publisher","DOI":"10.1001\/jamaoncol.2023.5410","article-title":"Pembrolizumab or placebo plus chemotherapy with or without bevacizumab for persistent, recurrent, or metastatic cervical cancer: subgroup analyses from the KEYNOTE-826 randomized clinical trial","volume":"10","author":"Tewari","year":"2024","journal-title":"JAMA Oncol"},{"key":"B40","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijrobp.2025.04.033","article-title":"Understanding hydronephrosis occurrence by an individual-kidney level analysis of all events post-chemoradiotherapy for locally advanced cervical cancer","volume":"123","author":"Sapienza","year":"2025","journal-title":"Int J Radiat oncology biology Phys"},{"key":"B41","doi-asserted-by":"publisher","DOI":"10.1007\/s40265-019-01249-z","article-title":"Novel therapeutics for recurrent cervical cancer: moving towards personalized therapy","volume":"80","author":"Cohen","year":"2020","journal-title":"Drugs"},{"key":"B42","doi-asserted-by":"publisher","DOI":"10.1097\/IGC.0b013e3182a80a07","article-title":"Platinum-free interval in second-line chemotherapy for recurrent cervical cancer","volume":"23","author":"Matoda","year":"2013","journal-title":"Int J gynecological Cancer"},{"key":"B43","doi-asserted-by":"publisher","first-page":"65","DOI":"10.1016\/j.ygyno.2008.03.009","article-title":"Evaluation of pemetrexed (Alimta, LY231514) as second line chemotherapy in persistent or recurrent carcinoma of the cervix: a phase II study of the Gynecologic Oncology Group","volume":"110","author":"Miller","year":"2008","journal-title":"Gynecologic Oncol"},{"key":"B44","doi-asserted-by":"publisher","DOI":"10.1097\/MD.0000000000010340","article-title":"The combination of cisplatin and topotecan as a second-line treatment for patients with advanced\/recurrent uterine cervix cancer","volume":"97","author":"Moon","year":"2018","journal-title":"Medicine"},{"key":"B45","doi-asserted-by":"publisher","DOI":"10.1007\/s12032-008-9108-5","article-title":"Weekly topotecan as second- or third-line treatment in patients with recurrent or metastatic cervical cancer","volume":"26","author":"Coronel","year":"2009","journal-title":"Med Oncol"},{"key":"B46","doi-asserted-by":"publisher","DOI":"10.1007\/s10637-019-00858-5","article-title":"Phase II study of apatinib, a novel tyrosine kinase inhibitor targeting tumor angiogenesis, as second-line treatment for recurrent or advanced cervical cancer patients","volume":"38","author":"Zhang","year":"2020","journal-title":"Investigational New Drugs"},{"key":"B47","doi-asserted-by":"publisher","DOI":"10.1080\/15384047.2015.1026483","article-title":"A pilot study of nimotuzumab plus single agent chemotherapy as second- or third-line treatment or more in patients with recurrent, persistent or metastatic cervical cancer","volume":"16","author":"Cetina","year":"2015","journal-title":"Cancer Biol Ther"},{"key":"B48","doi-asserted-by":"publisher","first-page":"697","DOI":"10.1158\/1078-0432.CCR-24-2343","article-title":"Human papilloma virus circulating cell-free DNA kinetics in patients with cervical cancer undergoing definitive chemoradiation","volume":"31","author":"Seo","year":"2025","journal-title":"Clin Cancer Res"},{"key":"B49","doi-asserted-by":"publisher","first-page":"101755","DOI":"10.1016\/j.ijgc.2025.101755","article-title":"Circulating human papillomavirus DNA sequencing as a biomarker of response in advanced cervical cancer","volume":"1","author":"Collier","year":"2025","journal-title":"Int J gynecological Cancer"},{"key":"B50","doi-asserted-by":"publisher","first-page":"e92","DOI":"10.3802\/jgo.2025.36.e92","article-title":"Significance of HPV status on tumor response and treatment outcomes in endocervical adenocarcinoma treated with definitive chemoradiotherapy: a retrospective study","volume":"36","author":"Baek","year":"2025","journal-title":"J gynecologic Oncol"},{"key":"B51","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2024.1371353","article-title":"Efficacy and safety of BVAC-C in HPV type 16- or 18-positive cervical carcinoma who failed 1st platinum-based chemotherapy: a phase I\/IIa study","volume":"15","author":"Choi","year":"2024","journal-title":"Front Immunol"},{"key":"B52","doi-asserted-by":"publisher","DOI":"10.1093\/oncolo\/oyad085","article-title":"Phase II trial of MEDI0457 and durvalumab for patients with recurrent\/metastatic human papillomavirus-associated cancers","volume":"28","author":"Morris","year":"2023","journal-title":"oncologist"},{"key":"B53","doi-asserted-by":"publisher","DOI":"10.1002\/cam4.70204","article-title":"The efficacy of first and second immunotherapy exposure in patients with recurrent or metastatic cervical cancer","volume":"13","author":"Ju","year":"2024","journal-title":"Cancer Med"},{"key":"B54","doi-asserted-by":"publisher","first-page":"321","DOI":"10.1186\/s12967-025-06277-w","article-title":"PD-L1(+) CD49f(+) CD133(+) Circulating tumor cells predict outcome of patients with vulvar or cervical cancer after radio- and chemoradiotherapy","volume":"23","author":"Gies","year":"2025","journal-title":"J Trans Med"},{"key":"B55","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2023.1195476","article-title":"The anti-PD-1 era of cervical cancer: achievement, opportunity, and challenge","volume":"14","author":"Li","year":"2023","journal-title":"Front Immunol"},{"key":"B56","doi-asserted-by":"publisher","first-page":"113268","DOI":"10.1016\/j.intimp.2024.113268","article-title":"Improved outcomes of palliative radiotherapy combined with immune checkpoint inhibitors in recurrent or metastatic cervical cancers","volume":"143","author":"Pan","year":"2024","journal-title":"Int Immunopharmacol"},{"key":"B57","doi-asserted-by":"publisher","first-page":"31528","DOI":"10.1038\/s41598-024-82976-6","article-title":"Systemic immune-inflammatory index predict short-term outcome in recurrent\/metastatic and locally advanced cervical cancer patients treated with PD-1 inhibitor","volume":"14","author":"Chen","year":"2024","journal-title":"Sci Rep"},{"key":"B58","doi-asserted-by":"publisher","first-page":"450","DOI":"10.1186\/s12885-025-13843-4","article-title":"The benefit and risk of addition of PD-1\/PD-L1 inhibitors to chemotherapy for advanced cervical cancer: a phase 3 randomized controlled trials based meta-analysis","volume":"25","author":"Luo","year":"2025","journal-title":"BMC cancer"},{"key":"B59","doi-asserted-by":"publisher","first-page":"e009898","DOI":"10.1136\/jitc-2024-009898","article-title":"Sintilimab plus HPV vaccine for recurrent or metastatic cervical cancer","volume":"12","author":"Wang","year":"2024","journal-title":"J immunotherapy Cancer"},{"key":"B60","doi-asserted-by":"publisher","DOI":"10.1016\/j.ygyno.2024.10.001","article-title":"Phase II study of enlonstobart (SG001), a novel PD-1 inhibitor in patients with PD-L1 positive recurrent\/metastatic cervical cancer","volume":"191","author":"Li","year":"2024","journal-title":"Gynecologic Oncol"},{"key":"B61","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.20.01920","article-title":"Camrelizumab plus apatinib in patients with advanced cervical cancer (CLAP): A multicenter, open-label, single-arm, phase II trial","volume":"38","author":"Lan","year":"2020","journal-title":"J Clin Oncol"},{"key":"B62","doi-asserted-by":"publisher","DOI":"10.1002\/cac2.12547","article-title":"Long-term survival outcomes and immune checkpoint inhibitor retreatment in patients with advanced cervical cancer treated with camrelizumab plus apatinib in the phase II CLAP study","volume":"44","author":"Lan","year":"2024","journal-title":"Cancer Commun"},{"key":"B63","doi-asserted-by":"publisher","first-page":"e002223","DOI":"10.1136\/jitc-2020-002223","article-title":"Genomic profiling of advanced cervical cancer to predict response to programmed death-1 inhibitor combination therapy: a secondary analysis of the CLAP trial","volume":"9","author":"Huang","year":"2021","journal-title":"J immunotherapy Cancer"},{"key":"B64","doi-asserted-by":"publisher","DOI":"10.4103\/jcrt.jcrt_1851_21","article-title":"Camrelizumab (SHR-1210) with carboplatin and albumin-binding paclitaxel in patients with metastatic or recurrent cervical cancer: An open-label, phase 2 trial","volume":"18","author":"Zhang","year":"2022","journal-title":"J Cancer Res Ther"},{"key":"B65","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejogrb.2024.07.036","article-title":"Prognostic value of human papillomavirus cell-free DNA in cervical cancer patients: A systematic review and meta-analysis","volume":"300","author":"Wang","year":"2024","journal-title":"Eur J obstetrics gynecology Reprod Biol"},{"key":"B66","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2024.1507977","article-title":"Efficacy and safety of adding immune checkpoint inhibitors to first-line standard therapy for recurrent or advanced cervical cancer: a meta-analysis of phase 3 clinical trials","volume":"15","author":"Zhang","year":"2024","journal-title":"Front Immunol"},{"key":"B67","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2024.1454372","article-title":"Efficacy of PD-1 or PD-L1 inhibitors for the therapy of cervical cancer with varying PD-L1 expression levels: a\u00a0single-arm meta-analysis","volume":"14","author":"Yang","year":"2024","journal-title":"Front Oncol"},{"key":"B68","doi-asserted-by":"publisher","DOI":"10.1016\/j.ygyno.2024.10.023","article-title":"Standard of care treatment for stage IVB cervical cancer: A systematic review and meta-analysis","volume":"191","author":"Hunsberger","year":"2024","journal-title":"Gynecologic Oncol"},{"key":"B69","doi-asserted-by":"publisher","DOI":"10.17305\/bb.2025.12597","article-title":"The immunotherapy breakthroughs in cervical cancer: Focus on potential biomarkers and further therapy advances","volume":"25","author":"Pezer Naletilic","year":"2025","journal-title":"Biomolecules biomedicine"},{"key":"B70","doi-asserted-by":"publisher","DOI":"10.1055\/a-2520-5736","article-title":"Evaluation of baseline characteristics and therapeutic management strategies in metastatic cervical cancer in Germany: A multicentric retrospective longitudinal observational study: A quality assurance initiative of the AGO-study group and AGO-OK uterus","volume":"85","author":"Denschlag","year":"2025","journal-title":"Geburtshilfe und Frauenheilkunde"},{"key":"B71","doi-asserted-by":"publisher","first-page":"180","DOI":"10.3390\/pharmacy12060180","article-title":"Addition of bevacizumab to chemotherapy and its impact on clinical efficacy in cervical cancer: A systematic review and meta-analysis","volume":"12","author":"Shahzad","year":"2024","journal-title":"Pharmacy"}],"container-title":["Frontiers in Immunology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2025.1679950\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,12,2]],"date-time":"2025-12-02T06:26:46Z","timestamp":1764656806000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2025.1679950\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,12,2]]},"references-count":71,"alternative-id":["10.3389\/fimmu.2025.1679950"],"URL":"https:\/\/doi.org\/10.3389\/fimmu.2025.1679950","relation":{},"ISSN":["1664-3224"],"issn-type":[{"value":"1664-3224","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,12,2]]},"article-number":"1679950"}}